Literature DB >> 29302360

Bio-artificial pleura using an autologous dermal fibroblast sheet.

Masato Kanzaki1, Ryo Takagi2, Kaoru Washio2, Mami Kokubo2, Masayuki Yamato2.   

Abstract

Air leaks (ALs) are observed after pulmonary resections, and without proper treatment, can produce severe complications. AL prevention is a critical objective for managing patients after pulmonary resection. This study applied autologous dermal fibroblast sheets (DFS) to close ALs. For sealing ALs in a 44-year-old male human patient with multiple bullae, a 5 × 15-mm section of skin was surgically excised. From this skin specimen, primary dermal fibroblasts were isolated and cultured for 4 weeks to produce DFSs that were harvested after a 10-day culture. ALs were completely sealed using surgical placement of these autologous DFSs. DFS were found to be a durable long-term AL sealant, exhibiting requisite flexibility, elasticity, durability, biocompatibility, and usability, resulting reliable AL closure. DFS should prove to be an extremely useful tissue-engineered pleura substitute.

Entities:  

Year:  2017        PMID: 29302360      PMCID: PMC5677916          DOI: 10.1038/s41536-017-0031-2

Source DB:  PubMed          Journal:  NPJ Regen Med        ISSN: 2057-3995


Air leaks (ALs) are frequently observed after pulmonary resections, especially video-assisted thoracoscopic surgeries (VATS). While often non-life-threatening, without proper treatment, ALs can progress to more severe complications.[1,2] Based on the STS National Database (General Thoracic Surgery Database), Attaar et al. reported an incidence rate of prolonged air leak (PAL) of 8.6%.[3] Furthermore, patients with PALs have significantly prolonged median lengths of hospital stays with the higher rates of in-hospital mortality. The authors previously reported a novel method of cell-sheet engineering of lung AL sealants using DFSs harvested from temperature-responsive culture dishes (TCDs).[4,5] This study demonstrates the first known application of autologous DFS for closing a human pleural defect. A 44-year-old male Japanese patient presenting with left chest pain and shortness of breath upon exercise over the preceding month was referred to the authors’ hospital with an infected bulla. Chest computed tomography (CT) revealed multiple bullae in his left upper lobe, and one of these bullae contained fluid (Fig. 1a). A 5 × 15-mm surgical skin excision harvested from the anticipated surgical incision site (Fig. 1b) was used to source primary human dermal fibroblasts were cultured on tissue-culture dishes for 4 weeks (Fig. 1c). Then, culture-expanded fibroblasts were seeded onto 35-mm TCDs, and confluent DFSs were harvested without enzyme treatment after a 10-day culture (Fig. 1d). On the day prior to surgery, freshly prepared DFSs were subjected to various quality assessments, including sterility, mycoplasma, and endotoxin tests. Simultaneously, DFSs were cultured for investigating the number, viability, and purity of cells by measuring vimentin-positive-cell rate by flow cytometry, and DFSs found to contain 99.8% human fibroblasts. The patient underwent VATS bullectomy with a stapler. AL from the resection stump was confirmed by observing air bubbles upon submergence with saline. All ALs were completely sealed using autologous DFSs, and a water seal test confirmed stable AL closure against up to 25 cm H2O (Fig. 1e). Using a digital drainage system, no AL was detected after surgery. The postoperative course was uncomplicated. CT at one month post-surgery revealed no air space (Fig. 1f). No event was observed for 7 months after surgery, and the patient was found to be in a healthy condition.
Fig. 1

a Chest CT revealed multiple bullae in patient’s left upper lobe. b A 5 × 15-mm piece of patient skin was surgically excised from the planned surgical location of the dermal incision for the surgical repair. c Phase contrast micrograph of autologous primary dermal fibroblasts cultured for 4 weeks. d Transplantable dermal fibroblast sheet (DFS) harvested after 10-day culture. e All intraoperative ALs were completely sealed by transplanted DFSs (white rectangle). f Patient chest CT at one month post-surgery showing no observable air space

a Chest CT revealed multiple bullae in patient’s left upper lobe. b A 5 × 15-mm piece of patient skin was surgically excised from the planned surgical location of the dermal incision for the surgical repair. c Phase contrast micrograph of autologous primary dermal fibroblasts cultured for 4 weeks. d Transplantable dermal fibroblast sheet (DFS) harvested after 10-day culture. e All intraoperative ALs were completely sealed by transplanted DFSs (white rectangle). f Patient chest CT at one month post-surgery showing no observable air space The methods were performed in accordance with relevant guidelines and regulations and approved by the ethics committee at Tokyo Women’s Medical University and by the Institutional Review Board for Clinical Research at Osaka University. Oral and written informed consents were obtained from the patient. This study was performed according to the Guidelines on clinical research using human stem cells established by the Ministry of Health, Labour, and Welfare, Japan, and registered with the University hospital Medical Information Network (UMIN) Clinical Trials Registry as No. UMIN000022554. PALs after lung resection have negative consequences on overall morbidity, cost, and hospitalization. Intraoperative ALs should be avoided using careful surgical techniques. Various methods are currently applied to intraoperative AL closure. Especially, fibrin glue (FG)-based techniques with FG with sheet materials are preferred to close AL in Japan. However, due to the inflexibility of materials, FG-techniques give unsuccessful results. For treating recurred PALs, pleurodesis is performed with antibiotic, etc. Having various extracellular-matrix proteins, fibroblast sheets adhere to the pleural surface and close postoperative AL. Autologous DFS was used as a durable long-term AL sealant that was flexible enough to move responding to the dynamic movement of lung during respiration. This study validated the efficacy of DFS as bio-artificial pleura, which sealed AL.
  5 in total

Review 1.  Predictors of alveolar air leaks.

Authors:  David B Loran; Kenneth J Woodside; Robert J Cerfolio; Joseph B Zwischenberger
Journal:  Chest Surg Clin N Am       Date:  2002-08

2.  Dynamic sealing of lung air leaks by the transplantation of tissue engineered cell sheets.

Authors:  Masato Kanzaki; Masayuki Yamato; Joseph Yang; Hidekazu Sekine; Chinatsu Kohno; Ryo Takagi; Hideyuki Hatakeyama; Tamami Isaka; Teruo Okano; Takamasa Onuki
Journal:  Biomaterials       Date:  2007-06-28       Impact factor: 12.479

3.  A clinical prediction model for prolonged air leak after pulmonary resection.

Authors:  Adam Attaar; Daniel G Winger; James D Luketich; Matthew J Schuchert; Inderpal S Sarkaria; Neil A Christie; Katie S Nason
Journal:  J Thorac Cardiovasc Surg       Date:  2016-10-14       Impact factor: 5.209

4.  Identifying Patients at Higher Risk of Prolonged Air Leak After Lung Resection.

Authors:  Sebastien Gilbert; Sonam Maghera; Andrew J Seely; Donna E Maziak; Farid M Shamji; Sudhir R Sundaresan; Patrick J Villeneuve
Journal:  Ann Thorac Surg       Date:  2016-07-22       Impact factor: 4.330

5.  Functional closure of visceral pleural defects by autologous tissue engineered cell sheets.

Authors:  Masato Kanzaki; Masayuki Yamato; Joseph Yang; Hidekazu Sekine; Ryo Takagi; Tamami Isaka; Teruo Okano; Takamasa Onuki
Journal:  Eur J Cardiothorac Surg       Date:  2008-06-30       Impact factor: 4.191

  5 in total
  9 in total

1.  A novel alveolar epithelial cell sheet fabricated under feeder-free conditions for potential use in pulmonary regenerative therapy.

Authors:  Shota Mitsuboshi; Jun Homma; Hidekazu Sekine; Ryo Takagi; Tatsuya Shimizu; Masato Kanzaki
Journal:  Regen Ther       Date:  2022-02-05       Impact factor: 3.651

2.  Effect of Temperature Changes on Serum Protein Adsorption on Thermoresponsive Cell-Culture Surfaces Monitored by A Quartz Crystal Microbalance with Dissipation.

Authors:  Jun Kobayashi; Yoshinori Arisaka; Nobuhiko Yui; Yoshikatsu Akiyama; Masayuki Yamato; Teruo Okano
Journal:  Int J Mol Sci       Date:  2018-05-18       Impact factor: 5.923

3.  The liver surface as a favorable site for islet cell sheet transplantation in type 1 diabetes model mice.

Authors:  Izumi Fujita; Rie Utoh; Masakazu Yamamoto; Teruo Okano; Masayuki Yamato
Journal:  Regen Ther       Date:  2018-05-10       Impact factor: 3.419

4.  Utah's cell sheet tissue engineering center.

Authors:  Kyungsook Kim; David W Grainger; Teruo Okano
Journal:  Regen Ther       Date:  2019-05-10       Impact factor: 3.419

5.  Phenotypic traits of mesenchymal stem cell sheets fabricated by temperature-responsive cell culture plate: structural characteristics of MSC sheets.

Authors:  Mitsuyoshi Nakao; Kyungsook Kim; Kenichi Nagase; David W Grainger; Hideko Kanazawa; Teruo Okano
Journal:  Stem Cell Res Ther       Date:  2019-11-28       Impact factor: 6.832

6.  Human mesenchymal stem cell sheets in xeno-free media for possible allogenic applications.

Authors:  Kyungsook Kim; Sophia Bou-Ghannam; Hallie Thorp; David W Grainger; Teruo Okano
Journal:  Sci Rep       Date:  2019-10-08       Impact factor: 4.379

7.  Cell Sheets Restore Secretory Function in Wounded Mouse Submandibular Glands.

Authors:  Harim T Dos Santos; Kyungsook Kim; Teruo Okano; Jean M Camden; Gary A Weisman; Olga J Baker; Kihoon Nam
Journal:  Cells       Date:  2020-12-09       Impact factor: 6.600

8.  Cell sheet transplantation prevents inflammatory adhesions: A new treatment for adhesive otitis media.

Authors:  Kazuhisa Yamamoto; Tsunetaro Morino; Yoshiyuki Kasai; Shun Kikuchi; Manabu Komori; Masayuki Yamato; Hiromi Kojima
Journal:  Regen Ther       Date:  2021-10-26       Impact factor: 3.419

9.  Pulsatile tubular cardiac tissues fabricated by wrapping human iPS cells-derived cardiomyocyte sheets.

Authors:  Shinpei Tsuruyama; Katsuhisa Matsuura; Katsuhisa Sakaguchi; Tatsuya Shimizu
Journal:  Regen Ther       Date:  2019-10-01       Impact factor: 3.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.